ADMA Biologics (NASDAQ:ADMA) Trading Down 8.8% - Should You Sell?

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report)'s stock price was down 8.8% on Monday . The company traded as low as $16.76 and last traded at $16.93. Approximately 554,779 shares changed hands during trading, a decline of 71% from the average daily volume of 1,946,501 shares. The stock had previously closed at $18.56.

Analyst Upgrades and Downgrades

ADMA has been the topic of a number of analyst reports. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Finally, Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th.

ADMA Biologics Stock Performance

The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company's 50-day moving average price is $19.39 and its two-hundred day moving average price is $17.15. The company has a market cap of $3.90 billion, a P/E ratio of 58.89 and a beta of 0.76.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million during the quarter, compared to analysts' expectations of $107.25 million. During the same period last year, the company posted $0.01 earnings per share. As a group, equities analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Brad L. Tade sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 3.70% of the company's stock.

Institutional Trading of ADMA Biologics

Several institutional investors have recently made changes to their positions in ADMA. Quest Partners LLC bought a new position in shares of ADMA Biologics in the second quarter valued at approximately $29,000. Hollencrest Capital Management acquired a new stake in shares of ADMA Biologics in the third quarter worth $30,000. Larson Financial Group LLC acquired a new stake in shares of ADMA Biologics in the third quarter worth $31,000. GAMMA Investing LLC grew its stake in shares of ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 967 shares during the last quarter. Finally, National Bank of Canada FI acquired a new stake in ADMA Biologics during the third quarter worth $35,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.